allelic ratio, 4.3 months vs low FLT3-ITD allelic ratio, 6.9 months). In both arms, overall survival was
longer in the low FLT3-ITD allelic ratio cohort than in the high FLT3-ITD allelic ratio cohort, but the
difference in the gilteritinib arm was not statistically significant (gilteritinib: hazard
ratio=1.341, P=0.0712; salvage chemotherapy: hazard ratio=2.01, P=0.0021).
Conclusions: The ADMIRAL trial shows that the clinical benefit of gilteritinib
in FLT3mut+ relapsed/refractory AML is maintained regardless of NPM1, DNMT3A, DNMT3A/NPM1,
or WT1 co-mut+ or high FLT3-ITD allelic ratio.
